The merlin interacting proteins reveal multiple targets for NF2 therapy

Evans, 1992, A genetic study of type 2 neurofibromatosis in the United Kingdom. I. Prevalence, mutation rate, fitness, and confirmation of maternal transmission effect on severity, J. Med. Genet., 29, 841, 10.1136/jmg.29.12.841 Narod, 1992, Neurofibromatosis type 2 appears to be a genetically homogeneous disease, Am. J. Hum. Genet., 51, 486 Martuza, 1988, Neurofibromatosis 2 (bilateral acoustic neurofibromatosis), N. Engl. J. Med., 318, 684, 10.1056/NEJM198803173181106 Evans, 1992, A clinical study of type 2 neurofibromatosis, Q. J. Med., 84, 603 Parry, 1994, Neurofibromatosis 2 (NF2): clinical characteristics of 63 affected individuals and clinical evidence for heterogeneity, Am. J. Med. Genet., 52, 450, 10.1002/ajmg.1320520411 Mautner, 1996, The neuroimaging and clinical spectrum of neurofibromatosis 2, Neurosurgery, 38, 880, 10.1097/00006123-199605000-00004 Rubio, 1994, Analysis of the neurofibromatosis 2 gene in human ependymomas and astrocytomas, Cancer Res., 54, 45 Ruttledge, 1994, Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas, Nat. Genet., 6, 180, 10.1038/ng0294-180 Sainz, 1994, Mutations of the neurofibromatosis type 2 gene and lack of the gene product in vestibular schwannomas, Hum. Mol. Genet., 3, 885, 10.1093/hmg/3.6.885 Bijlsma, 1994, Analysis of mutations in the SCH gene in schwannomas, Genes Chromosomes Cancer, 11, 7, 10.1002/gcc.2870110103 Papi, 1995, Somatic mutations in the neurofibromatosis type 2 gene in sporadic meningiomas, Hum. Genet., 95, 347, 10.1007/BF00225206 Rouleau, 1993, Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2, Nature, 363, 515, 10.1038/363515a0 Trofatter, 1993, A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor, Cell, 75, 826 Bianchi, 1994, Mutations in transcript isoforms of the neurofibromatosis 2 gene in multiple human tumour types, Nat. Genet., 6, 185, 10.1038/ng0294-185 Huynh, 1994, Alternative transcripts in the mouse neurofibromatosis type 2 (NF2) gene are conserved and code for schwannomins with distinct C-terminal domains, Hum. Mol. Genet., 3, 1075, 10.1093/hmg/3.7.1075 Pykett, 1994, The neurofibromatosis 2 (NF2) tumor suppressor gene encodes multiple alternatively spliced transcripts, Hum. Mol. Genet., 3, 559, 10.1093/hmg/3.4.559 Schmucker, 1999, Novel alternatively spliced isoforms of the neurofibromatosis type 2 tumor suppressor are targeted to the nucleus and cytoplasmic granules, Hum. Mol. Genet., 8, 1561, 10.1093/hmg/8.8.1561 Chang, 2002, Multiple transcription initiation sites, alternative splicing, and differential polyadenylation contribute to the complexity of human neurofibromatosis 2 transcripts, Genomics, 79, 63, 10.1006/geno.2001.6672 Berryman, 1995, Ezrin oligomers are major cytoskeletal components of placental microvilli: a proposal for their involvement in cortical morphogenesis, J. Cell Biol., 131, 1231, 10.1083/jcb.131.5.1231 Huang, 1998, Merlin differs from moesin in binding to F-actin and in its intra- and intermolecular interactions, Biochem. Biophys. Res. Commun., 248, 548, 10.1006/bbrc.1998.9009 Gutmann, 2001, The NF2 interactor, hepatocyte growth factor-regulated tyrosine kinase substrate (HRS), associates with merlin in the “open” conformation and suppresses cell growth and motility, Hum. Mol. Genet., 10, 825, 10.1093/hmg/10.8.825 Gronholm, 1999, Homotypic and heterotypic interaction of the neurofibromatosis 2 tumor suppressor protein merlin and the ERM protein ezrin, J. Cell Sci., 112, 895, 10.1242/jcs.112.6.895 Gonzalez-Agosti, 1999, Interdomain interaction of merlin isoforms and its influence on intermolecular binding to NHE-RF, J. Biol. Chem., 274, 34438, 10.1074/jbc.274.48.34438 Gary, 1995, Ezrin self-association involves binding of an N-terminal domain to a normally masked C-terminal domain that includes the F-actin binding site, Mol. Biol. Cell, 6, 1061, 10.1091/mbc.6.8.1061 Reczek, 1997, Identification of EBP50: a PDZ-containing phosphoprotein that associates with members of the ezrin–radixin–moesin family, J. Cell Biol., 139, 169, 10.1083/jcb.139.1.169 Gutmann, 1999, Increased expression of the NF2 tumor suppressor gene product, merlin, impairs cell motility, adhesion and spreading, Hum. Mol. Genet., 8, 267, 10.1093/hmg/8.2.267 Sherman, 1997, Interdomain binding mediates tumor growth suppression by the NF2 gene product, Oncogene, 15, 2505, 10.1038/sj.onc.1201418 Bashour, 2002, The neurofibromatosis type 2 gene product, merlin, reverses the F-actin cytoskeletal defects in primary human Schwannoma cells, Mol. Cell. Biol., 22, 1150, 10.1128/MCB.22.4.1150-1157.2002 Brault, 2001, Normal membrane localization and actin association of the NF2 tumor suppressor protein are dependent on folding of its N-terminal domain, J. Cell Sci., 114, 1901, 10.1242/jcs.114.10.1901 Matsui, 1998, Rho-kinase phosphorylates COOH-terminal threonines of ezrin/radixin/moesin (ERM) proteins and regulates their head-to-tail association, J. Cell Biol., 140, 647, 10.1083/jcb.140.3.647 Simons, 1998, C-terminal threonine phosphorylation activates ERM proteins to link the cell's cortical lipid bilayer to the cytoskeleton, Biochem. Biophys. Res. Commun., 253, 561, 10.1006/bbrc.1998.9823 Kissil, 2002, Merlin phosphorylation by p21-activated kinase 2 and effects of phosphorylation on merlin localization, J. Biol. Chem., 277, 10394, 10.1074/jbc.M200083200 Kissil, 2003, Merlin, the product of the Nf2 tumor suppressor gene, is an inhibitor of the p21-activated kinase, Pak1, Mol. Cell, 12, 841, 10.1016/S1097-2765(03)00382-4 Xiao, 2002, p21-activated kinase links Rac/Cdc42 signaling to merlin, J. Biol. Chem., 277, 883, 10.1074/jbc.C100553200 Alfthan, 2004, Cyclic AMP-dependent protein kinase phosphorylates merlin at serine 518 independently of p21-activated kinase and promotes merlin–ezrin heterodimerization, J. Biol. Chem., 279, 18559, 10.1074/jbc.M313916200 Shaw, 2001, The Nf2 tumor suppressor, merlin, functions in Rac-dependent signaling, Dev. Cell, 1, 63, 10.1016/S1534-5807(01)00009-0 Morrison, 2001, The NF2 tumor suppressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44, Genes Dev., 15, 968, 10.1101/gad.189601 Kumar, 2006, p21-activated kinases in cancer, Nat. Rev. Cancer, 6, 459, 10.1038/nrc1892 Tikoo, 1994, An anti-Ras function of neurofibromatosis type 2 gene product (NF2/Merlin), J. Biol. Chem., 269, 23387, 10.1016/S0021-9258(17)31525-9 Hirokawa, 2004, A clue to the therapy of neurofibromatosis type 2: NF2/merlin is a PAK1 inhibitor, Cancer J., 10, 20, 10.1097/00130404-200401000-00006 Hartshorne, 1998, Myosin light chain phosphatase: subunit composition, interactions and regulation, J. Muscle Res. Cell Motil., 19, 325, 10.1023/A:1005385302064 Jin, 2006, Tumorigenic transformation by CPI-17 through inhibition of a merlin phosphatase, Nature, 442, 576, 10.1038/nature04856 Kimura, 1998, The involvement of calpain-dependent proteolysis of the tumor suppressor NF2 (merlin) in schwannomas and meningiomas, Nat. Med., 4, 915, 10.1038/nm0898-915 Kimura, 2000, Calpain-dependent proteolysis of NF2 protein: involvement in schwannomas and meningiomas, Neuropathology, 20, 153, 10.1046/j.1440-1789.2000.00326.x Kaneko, 2001, Calpain-dependent proteolysis of merlin occurs by oxidative stress in meningiomas: a novel hypothesis of tumorigenesis, Cancer, 92, 2662, 10.1002/1097-0142(20011115)92:10<2662::AID-CNCR1620>3.0.CO;2-9 Ueki, 1999, Tight association of loss of merlin expression with loss of heterozygosity at chromosome 22q in sporadic meningiomas, Cancer Res., 59, 5995 Evans, 2001, Molecular alterations in the neurofibromatosis type 2 gene and its protein rarely occurring in meningothelial meningiomas, J. Neurosurg., 94, 111, 10.3171/jns.2001.94.1.0111 Turunen, 1994, Ezrin has a COOH-terminal actin-binding site that is conserved in the ezrin protein family, J. Cell Biol., 126, 1445, 10.1083/jcb.126.6.1445 Xu, 1998, Merlin differentially associates with the microtubule and actin cytoskeleton, J. Neurosci. Res., 51, 403, 10.1002/(SICI)1097-4547(19980201)51:3<403::AID-JNR13>3.0.CO;2-7 Deguen, 1998, Impaired interaction of naturally occurring mutant NF2 protein with actin-based cytoskeleton and membrane, Hum. Mol. Genet., 7, 217, 10.1093/hmg/7.2.217 James, 2001, The neurofibromatosis 2 protein product merlin selectively binds F-actin but not G-actin, and stabilizes the filaments through a lateral association, Biochem. J., 356, 377, 10.1042/0264-6021:3560377 Pelton, 1998, Ruffling membrane, stress fiber, cell spreading and proliferation abnormalities in human Schwannoma cells, Oncogene, 17, 2195, 10.1038/sj.onc.1202141 Hall, 1998, Rho GTPases and the actin cytoskeleton, Science, 279, 509, 10.1126/science.279.5350.509 Manchanda, 2005, The NF2 tumor suppressor Merlin and the ERM proteins interact with N-WASP and regulate its actin polymerization function, J. Biol. Chem., 280, 12517, 10.1074/jbc.C400583200 Sangerman, 2001, Spectrin ubiquitination and oxidative stress: potential roles in blood and neurological disorders, Cell. Mol. Biol. Lett., 6, 607 Scoles, 1998, Neurofibromatosis 2 tumour suppressor schwannomin interacts with betaII-spectrin, Nat. Genet., 18, 354, 10.1038/ng0498-354 Morcos, 1997, Characterization of fodrin interaction with the NF2 tumor suppressor gene product schwannomin (merlin) and varying strengths of protein binding that correlate with NF2 patient phenotypes., Neurology, 48, A393 Neill, 2001, Binding of the merlin-I product of the neurofibromatosis type 2 tumour suppressor gene to a novel site in beta-fodrin is regulated by association between merlin domains, Biochem. J., 358, 727, 10.1042/0264-6021:3580727 Chen, 2001, A novel isoform of beta-spectrin II localizes to cerebellar Purkinje-cell bodies and interacts with neurofibromatosis type 2 gene product schwannomin, J. Mol. Neurosci., 17, 59, 10.1385/JMN:17:1:59 Robb, 2003, Identification of a third Protein 4.1 tumor suppressor, Protein 4.1R, in meningioma pathogenesis, Neurobiol. Dis., 13, 191, 10.1016/S0969-9961(03)00071-8 Gutmann, 1998, Defects in neurofibromatosis 2 protein function can arise at multiple levels, Hum. Mol. Genet., 7, 335, 10.1093/hmg/7.3.335 MacDougall, 2001, Merlin, the Drosophila homologue of neurofibromatosis-2, is specifically required in posterior follicle cells for axis formation in the oocyte, Development, 128, 665, 10.1242/dev.128.5.665 Muranen, 2007, The tumor suppressor merlin interacts with microtubules and modulates Schwann cell microtubule cytoskeleton, Hum. Mol. Genet., 16, 1742, 10.1093/hmg/ddm122 Nguyen, 2001, Hierarchy of merlin and ezrin N- and C-terminal domain interactions in homo- and heterotypic associations and their relationship to binding of scaffolding proteins EBP50 and E3KARP, J. Biol. Chem., 276, 7621, 10.1074/jbc.M006708200 Meng, 2000, Interaction between two isoforms of the NF2 tumor suppressor protein, merlin, and between merlin and ezrin, suggests modulation of ERM proteins by merlin, J. Neurosci. Res., 62, 491, 10.1002/1097-4547(20001115)62:4<491::AID-JNR3>3.0.CO;2-D Welling, 2002, cDNA microarray analysis of vestibular schwannomas, Otol. Neurotol., 23, 736, 10.1097/00129492-200209000-00022 Tsukita, 1994, ERM family members as molecular linkers between the cell surface glycoprotein CD44 and actin-based cytoskeletons, J. Cell Biol., 126, 391, 10.1083/jcb.126.2.391 Sainio, 1997, Neurofibromatosis 2 tumor suppressor protein colocalizes with ezrin and CD44 and associates with actin-containing cytoskeleton, J. Cell Sci., 110, 2249, 10.1242/jcs.110.18.2249 Bai, 2007, Inhibition of the hyaluronan–CD44 interaction by merlin contributes to the tumor-suppressor activity of merlin, Oncogene, 26, 836, 10.1038/sj.onc.1209849 Bono, 2001, Layilin, a novel integral membrane protein, is a hyaluronan receptor, Mol. Biol. Cell, 12, 891, 10.1091/mbc.12.4.891 Borowsky, 1998, Layilin, a novel talin-binding transmembrane protein homologous with C-type lectins, is localized in membrane ruffles, J. Cell Biol., 143, 429, 10.1083/jcb.143.2.429 Bono, 2005, Layilin, a cell surface hyaluronan receptor, interacts with merlin and radixin, Exp. Cell Res., 308, 177, 10.1016/j.yexcr.2005.04.017 Kozak, 1995, Genetic mapping in human and mouse of the locus encoding TRBP, a protein that binds the TAR region of the human immunodeficiency virus (HIV-1), Genomics, 25, 66, 10.1016/0888-7543(95)80110-8 Benkirane, 1997, Oncogenic potential of TAR RNA binding protein TRBP and its regulatory interaction with RNA-dependent protein kinase PKR, EMBO J., 16, 611, 10.1093/emboj/16.3.611 Eckmann, 1997, Xlrbpa, a double-stranded RNA-binding protein associated with ribosomes and heterogeneous nuclear RNPs, J. Cell Biol., 138, 239, 10.1083/jcb.138.2.239 Park, 1994, TAR RNA-binding protein is an inhibitor of the interferon-induced protein kinase PKR, Proc. Natl. Acad. Sci. U. S. A., 91, 4713, 10.1073/pnas.91.11.4713 Langland, 2006, Inhibition of PKR by RNA and DNA viruses, Virus Res., 119, 100, 10.1016/j.virusres.2005.10.014 Rosenwald, 1995, Growth factor-independent expression of the gene encoding eukaryotic translation initiation factor 4E in transformed cell lines, Cancer Lett., 98, 77, 10.1016/S0304-3835(06)80013-3 Rosenwald, 2003, Expression of translation initiation factor eIF-2alpha is increased in benign and malignant melanocytic and colonic epithelial neoplasms, Cancer, 98, 1080, 10.1002/cncr.11619 Lee, 2004, Merlin, a tumor suppressor, interacts with transactivation-responsive RNA-binding protein and inhibits its oncogenic activity, J. Biol. Chem., 279, 30265, 10.1074/jbc.M312083200 Jeffrey, 1995, Nuclear localization of the interferon-inducible protein kinase PKR in human cells and transfected mouse cells, Exp. Cell Res., 218, 17, 10.1006/excr.1995.1126 Scoles, 2006, Schwannomin inhibits tumorigenesis through direct interaction with the eukaryotic initiation factor subunit c (eIF3c), Hum. Mol. Genet., 15, 1059, 10.1093/hmg/ddl021 Holz, 2005, mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events, Cell, 123, 569, 10.1016/j.cell.2005.10.024 Peterson, 2005, eIF3: a connecTOR of S6K1 to the translation preinitiation complex, Mol. Cell, 20, 655, 10.1016/j.molcel.2005.11.016 Hidalgo, 2000, The rapamycin-sensitive signal transduction pathway as a target for cancer therapy, Oncogene, 19, 6680, 10.1038/sj.onc.1204091 Wiederrecht, 1995, Mechanism of action of rapamycin: new insights into the regulation of G1-phase progression in eukaryotic cells, Prog. Cell Cycle Res., 1, 53, 10.1007/978-1-4615-1809-9_5 Hou, 2000, Protein 4.1R binding to eIF3-p44 suggests an interaction between the cytoskeletal network and the translation apparatus, Blood, 96, 747, 10.1182/blood.V96.2.747 Nupponen, 2000, Mapping the amplification of EIF3S3 in breast and prostate cancer, Genes Chromosomes Cancer, 28, 203, 10.1002/(SICI)1098-2264(200006)28:2<203::AID-GCC9>3.0.CO;2-X Saramaki, 2001, Amplification of EIF3S3 gene is associated with advanced stage in prostate cancer, Am. J. Pathol., 159, 2089, 10.1016/S0002-9440(10)63060-X Lin, 2001, Molecular interaction between human tumor marker protein p150, the largest subunit of eIF3, and intermediate filament protein K7, J. Cell. Biochem., 80, 483, 10.1002/1097-4644(20010315)80:4<483::AID-JCB1002>3.0.CO;2-B Pincheira, 2001, Identification of a 170-kDa protein over-expressed in lung cancers, Br. J. Cancer, 84, 1520, 10.1054/bjoc.2001.1828 Asano, 1997, The translation initiation factor eIF3-p48 subunit is encoded by int-6, a site of frequent integration by the mouse mammary tumor virus genome, J. Biol. Chem., 272, 23477, 10.1074/jbc.272.38.23477 Morris-Desbois, 1999, Interaction between the Ret finger protein and the Int-6 gene product and co-localisation into nuclear bodies, J. Cell Sci., 112, 3331, 10.1242/jcs.112.19.3331 Mayeur, 2002, Malignant transformation by the eukaryotic translation initiation factor 3 subunit p48 (eIF3e), FEBS Lett., 514, 49, 10.1016/S0014-5793(02)02307-4 Hoareau Alves, 2002, Association of the mammalian proto-oncoprotein Int-6 with the three protein complexes eIF3, COP9 signalosome and 26S proteasome, FEBS Lett., 527, 15, 10.1016/S0014-5793(02)03147-2 Rothe, 2000, Eukaryotic initiation factor 3 p110 mRNA is overexpressed in testicular seminomas, Am. J. Pathol., 157, 1597, 10.1016/S0002-9440(10)64797-9 Fronhoffs, 2002, A method for the rapid construction of cRNA standard curves in quantitative real-time reverse transcription polymerase chain reaction, Mol. Cell. Probes, 16, 99, 10.1006/mcpr.2002.0405 Loftus, 1999, Genome duplications and other features in 12 Mb of DNA sequence from human chromosome 16p and 16q, Genomics, 60, 295, 10.1006/geno.1999.5927 Ahn, 2005, PIKE GTPase signaling and function, Int. J. Biol. Sci., 1, 44, 10.7150/ijbs.1.44 Rong, 2003, PI3 kinase enhancer-Homer complex couples mGluRI to PI3 kinase, preventing neuronal apoptosis, Nat. Neurosci., 6, 1153, 10.1038/nn1134 Ye, 2000, Pike. A nuclear gtpase that enhances PI3kinase activity and is regulated by protein 4.1N, Cell, 103, 919, 10.1016/S0092-8674(00)00195-1 Rong, 2004, Neurofibromatosis 2 (NF2) tumor suppressor merlin inhibits phosphatidylinositol 3-kinase through binding to PIKE-L, Proc. Natl. Acad. Sci. U. S. A., 101, 18200, 10.1073/pnas.0405971102 Jannatipour, 2001, Schwannomin isoform-1 interacts with syntenin via PDZ domains, J. Biol. Chem., 276, 33093, 10.1074/jbc.M105792200 Geijsen, 2001, Cytokine-specific transcriptional regulation through an IL-5Ralpha interacting protein, Science, 293, 1136, 10.1126/science.1059157 Lin, 1999, The carboxyl terminus of B class ephrins constitutes a PDZ domain binding motif, J. Biol. Chem., 274, 3726, 10.1074/jbc.274.6.3726 Koroll, 2001, The neural cell recognition molecule neurofascin interacts with syntenin-1 but not with syntenin-2, both of which reveal self-associating activity, J. Biol. Chem., 276, 10646, 10.1074/jbc.M010647200 Grootjans, 1997, Syntenin, a PDZ protein that binds syndecan cytoplasmic domains, Proc. Natl. Acad. Sci. U. S. A., 94, 13683, 10.1073/pnas.94.25.13683 Leivonen, 2004, Prognostic value of syndecan-1 expression in breast cancer, Oncology, 67, 11, 10.1159/000080280 Volkmer, 1998, Dissection of complex molecular interactions of neurofascin with axonin-1, F11, and tenascin-R, which promote attachment and neurite formation of tectal cells, J. Cell Biol., 142, 1083, 10.1083/jcb.142.4.1083 Fialka, 1999, Identification of syntenin as a protein of the apical early endocytic compartment in Madin–Darby canine kidney cells, J. Biol. Chem., 274, 26233, 10.1074/jbc.274.37.26233 Scoles, 2000, The neurofibromatosis 2 tumor suppressor protein interacts with hepatocyte growth factor-regulated tyrosine kinase substrate, Hum. Mol. Genet., 9, 1567, 10.1093/hmg/9.11.1567 Zimmermann, 2005, Syndecan recycling [corrected] is controlled by syntenin-PIP2 interaction and Arf6, Dev. Cell, 9, 377, 10.1016/j.devcel.2005.07.011 Koo, 2002, Syntenin is overexpressed and promotes cell migration in metastatic human breast and gastric cancer cell lines, Oncogene, 21, 4080, 10.1038/sj.onc.1205514 Boukerche, 2007, mda-9/Syntenin regulates the metastatic phenotype in human melanoma cells by activating nuclear factor-kappaB, Cancer Res., 67, 1812, 10.1158/0008-5472.CAN-06-3875 Weinman, 1993, CAMP-mediated inhibition of the renal brush border membrane Na+–H+ exchanger requires a dissociable phosphoprotein cofactor, J. Clin. Invest., 92, 1781, 10.1172/JCI116767 Weinman, 1995, Characterization of a protein cofactor that mediates protein kinase A regulation of the renal brush border membrane Na+–H+ exchanger, J. Clin. Invest., 95, 2143, 10.1172/JCI117903 Yun, 1997, cAMP-mediated inhibition of the epithelial brush border Na+–H+ exchanger, NHE3, requires an associated regulatory protein, Proc. Natl. Acad. Sci. U. S. A., 94, 3010, 10.1073/pnas.94.7.3010 Zizak, 1999, cAMP-induced phosphorylation and inhibition of Na+–H+ exchanger 3 (NHE3) are dependent on the presence but not the phosphorylation of NHE regulatory factor, J. Biol. Chem., 274, 24753, 10.1074/jbc.274.35.24753 Murthy, 1998, NHE-RF, a regulatory cofactor for Na+–H+ exchange, is a common interactor for merlin and ERM (MERM) proteins, J. Biol. Chem., 273, 1273, 10.1074/jbc.273.3.1273 Weinman, 2003, A C-terminal PDZ motif in NHE3 binds NHERF-1 and enhances cAMP inhibition of sodium–hydrogen exchange, Biochemistry, 42, 12662, 10.1021/bi035244l Rangwala, 2005, Erbin regulates mitogen-activated protein (MAP) kinase activation and MAP kinase-dependent interactions between Merlin and adherens junction protein complexes in Schwann cells, J. Biol. Chem., 280, 11790, 10.1074/jbc.M414154200 Lallemand, 2003, NF2 deficiency promotes tumorigenesis and metastasis by destabilizing adherens junctions, Genes Dev., 17, 1090, 10.1101/gad.1054603 Chien, 2003, RAL GTPases are linchpin modulators of human tumour-cell proliferation and survival, EMBO Rep., 4, 800, 10.1038/sj.embor.embor899 Wolthuis, 1999, Ras caught in another affair: the exchange factors for Ral, Curr. Opin. Genet. Dev., 9, 112, 10.1016/S0959-437X(99)80016-1 Gonzalez-Garcia, 2005, RalGDS is required for tumor formation in a model of skin carcinogenesis, Cancer Cells, 7, 219, 10.1016/j.ccr.2005.01.029 Humphrey, 1997, Cloning and evaluation of RALGDS as a candidate for the tuberous sclerosis gene TSC1, Ann. Hum. Genet., 61, 299, 10.1017/S0003480097006246 Blair, 2000, A gene for autosomal dominant juvenile amyotrophic lateral sclerosis (ALS4) localizes to a 500-kb interval on chromosome 9q34, Neurogenetics, 3, 1, 10.1007/PL00022976 Ryu, 2005, The merlin tumor suppressor interacts with Ral guanine nucleotide dissociation stimulator and inhibits its activity, Oncogene, 24, 5355, 10.1038/sj.onc.1208633 Liu, 2002, Identification of a novel endothelial-derived gene EG-1, Biochem. Biophys. Res. Commun., 290, 602, 10.1006/bbrc.2001.6119 Wiederhold, 2004, Magicin, a novel cytoskeletal protein associates with the NF2 tumor suppressor merlin and Grb2, Oncogene, 23, 8815, 10.1038/sj.onc.1208110 Li, 2005, Immunohistochemical characterisation of differentiated CAD cells: expression of peptides and chromogranins, Histochem. Cell Biol., 124, 25, 10.1007/s00418-005-0017-9 Lu, 2005, The novel gene EG-1 stimulates cellular proliferation, Cancer Res., 65, 6159, 10.1158/0008-5472.CAN-04-4016 Zhang, 2004, Expression pattern of the novel gene EG-1 in cancer, Clin. Cancer Res., 10, 3504, 10.1158/1078-0432.CCR-03-0467 Chadee, 2006, Mixed-lineage kinase 3 regulates B-Raf through maintenance of the B-Raf/Raf-1 complex and inhibition by the NF2 tumor suppressor protein, Proc. Natl. Acad. Sci. U. S. A., 103, 4463, 10.1073/pnas.0510651103 Lim, 2006, Merlin inhibits growth hormone-regulated Raf-ERKs pathways by binding to Grb2 protein, Biochem. Biophys. Res. Commun., 340, 1151, 10.1016/j.bbrc.2005.12.122 Toby, 2003, A novel RING finger protein, human enhancer of invasion 10, alters mitotic progression through regulation of cyclin B levels, Mol. Cell. Biol., 23, 2109, 10.1128/MCB.23.6.2109-2122.2003 Gronholm, 2006, A functional association between merlin and HEI10, a cell cycle regulator, Oncogene, 25, 4389, 10.1038/sj.onc.1209475 Kressel, 2002, Nucleocytoplasmic transfer of the NF2 tumor suppressor protein merlin is regulated by exon 2 and a CRM1-dependent nuclear export signal in exon 15, Hum. Mol. Genet., 11, 2269, 10.1093/hmg/11.19.2269 Kudo, 1997, Molecular cloning and cell cycle-dependent expression of mammalian CRM1, a protein involved in nuclear export of proteins, J. Biol. Chem., 272, 29742, 10.1074/jbc.272.47.29742 Singh, 2007, HEI10 negatively regulates cell invasion by inhibiting cyclin B/Cdk1 and other promotility proteins, Oncogene, 26, 4825, 10.1038/sj.onc.1210282 Hara, 1993, The UDP-galactose translocator gene is mapped to band Xp11.23-p11.22 containing the Wiskott–Aldrich syndrome locus, Somat. Cell Mol. Genet., 19, 571, 10.1007/BF01233383 Kwan, 1991, Localization of the gene for the Wiskott–Aldrich syndrome between two flanking markers, TIMP and DXS255, on Xp11.22-Xp11.3, Genomics, 10, 29, 10.1016/0888-7543(91)90480-3 Rohatgi, 1999, The interaction between N-WASP and the Arp2/3 complex links Cdc42-dependent signals to actin assembly, Cell, 97, 221, 10.1016/S0092-8674(00)80732-1 Greer, 1996, Identification of WASP mutations, mutation hotspots and genotype–phenotype disparities in 24 patients with the Wiskott–Aldrich syndrome, Hum. Genet., 98, 685, 10.1007/s004390050285 Lee, 2004, MAP, a protein interacting with a tumor suppressor, merlin, through the run domain, Biochem. Biophys. Res. Commun., 325, 774, 10.1016/j.bbrc.2004.10.095 Pan, 2006, TBC-domain GAPs for Rab GTPases accelerate GTP hydrolysis by a dual-finger mechanism, Nature, 442, 303, 10.1038/nature04847 Mari, 2001, Role of the FYVE finger and the RUN domain for the subcellular localization of Rabip4, J. Biol. Chem., 276, 42501, 10.1074/jbc.M104885200 Yang, 2002, Interaction between tyrosine kinase Etk and a RUN domain- and FYVE domain-containing protein RUFY1. A possible role of ETK in regulation of vesicle trafficking, J. Biol. Chem., 277, 30219, 10.1074/jbc.M111933200 Sakamoto, 2005, The Caenorhabditis elegans UNC-14 RUN domain protein binds to the kinesin-1 and UNC-16 complex and regulates synaptic vesicle localization, Mol. Biol. Cell, 16, 483, 10.1091/mbc.E04-07-0553 Hall, 1992, Ras-related GTPases and the cytoskeleton, Mol. Biol. Cell, 3, 475, 10.1091/mbc.3.5.475 Leffers, 1993, Identification of two human Rho GDP dissociation inhibitor proteins whose overexpression leads to disruption of the actin cytoskeleton, Exp. Cell Res., 209, 165, 10.1006/excr.1993.1298 Fukumoto, 1990, Molecular cloning and characterization of a novel type of regulatory protein (GDI) for the rho proteins, ras p21-like small GTP-binding proteins, Oncogene, 5, 1321 Takahashi, 1997, Direct interaction of the Rho GDP dissociation inhibitor with ezrin/radixin/moesin initiates the activation of the Rho small G protein, J. Biol. Chem., 272, 23371, 10.1074/jbc.272.37.23371 Maeda, 1999, Expression level, subcellular distribution and rho-GDI binding affinity of merlin in comparison with ezrin/radixin/moesin proteins, Oncogene, 18, 4788, 10.1038/sj.onc.1202871 Fritz, 2002, Rho GTPases in human breast tumours: expression and mutation analyses and correlation with clinical parameters, Br. J. Cancer, 87, 635, 10.1038/sj.bjc.6600510 Obremski, 1998, Merlin, the neurofibromatosis type 2 gene product, and beta1 integrin associate in isolated and differentiating Schwann cells, J. Neurobiol., 37, 487, 10.1002/(SICI)1097-4695(199812)37:4<487::AID-NEU1>3.0.CO;2-B Fernandez-Valle, 2002, Paxillin binds schwannomin and regulates its density-dependent localization and effect on cell morphology, Nat. Genet., 31, 354, 10.1038/ng930 Scoles, 2005, HRS inhibits EGF receptor signaling in the RT4 rat schwannoma cell line, Biochem. Biophys. Res. Commun., 335, 385, 10.1016/j.bbrc.2005.07.083 Curto, 2007, Contact-dependent inhibition of EGFR signaling by Nf2/Merlin, J. Cell Biol., 177, 893, 10.1083/jcb.200703010 Sun, 2002, Functional analysis of the relationship between the neurofibromatosis 2 tumor suppressor and its binding partner, hepatocyte growth factor-regulated tyrosine kinase substrate, Hum. Mol. Genet., 11, 3167, 10.1093/hmg/11.25.3167 Scoles, 2002, Neurofibromatosis 2 (NF2) tumor suppressor schwannomin and its interacting protein HRS regulate STAT signaling, Hum. Mol. Genet., 11, 3179, 10.1093/hmg/11.25.3179 Lloyd, 2002, Hrs regulates endosome membrane invagination and tyrosine kinase receptor signaling in Drosophila, Cell, 108, 261, 10.1016/S0092-8674(02)00611-6 Bache, 2003, STAM and Hrs are subunits of a multivalent ubiquitin-binding complex on early endosomes, J. Biol. Chem., 278, 12513, 10.1074/jbc.M210843200 Michelsen, 2004, TLR signaling: an emerging bridge from innate immunity to atherogenesis, J. Immunol., 173, 5901, 10.4049/jimmunol.173.10.5901 Hsu, 2004, The protein kinase PKR is required for macrophage apoptosis after activation of Toll-like receptor 4, Nature, 428, 341, 10.1038/nature02405 Asakura, 2006, Serine/threonine kinase PKR: a sentinel kinase that discriminates a signaling pathway mediated by TLR4 from those mediated by TLR3 and TLR9, Am. J. Hematol., 82, 640, 10.1002/ajh.20817 Mehlen, 2005, Netrin PIPes up, Nat. Cell Biol., 7, 1052, 10.1038/ncb1105-1052 Martin, 2006, DCC regulates cell adhesion in human colon cancer derived HT-29 cells and associates with ezrin, Eur J. Cell Biol., 85, 769, 10.1016/j.ejcb.2006.02.013 Barret, 2000, Mutagenesis of the phosphatidylinositol 4,5-bisphosphate (PIP(2)) binding site in the NH(2)-terminal domain of ezrin correlates with its altered cellular distribution, J. Cell Biol., 151, 1067, 10.1083/jcb.151.5.1067 Lee, 2007, Identification and characterization of putative tumor suppressor NGB, a GTP-binding protein that interacts with the neurofibromatosis 2 protein, Mol. Cell. Biol., 27, 2103, 10.1128/MCB.00572-06 Gautreau, 2002, Mutant products of the NF2 tumor suppressor gene are degraded by the ubiquitin–proteasome pathway, J. Biol. Chem., 277, 31279, 10.1074/jbc.C200125200 Xiao, 2005, The NF2 tumor suppressor gene product, merlin, inhibits cell proliferation and cell cycle progression by repressing cyclin D1 expression, Mol. Cell. Biol., 25, 2384, 10.1128/MCB.25.6.2384-2394.2005 Graff, 2003, Translational control and metastatic progression: enhanced activity of the mRNA cap-binding protein eIF-4E selectively enhances translation of metastasis-related mRNAs, Clin. Exp. Metastasis, 20, 265, 10.1023/A:1022943419011 Boedigheimer, 1993, Expanded, a negative regulator of cell proliferation in Drosophila, shows homology to the NF2 tumor suppressor, Mech. Dev., 44, 83, 10.1016/0925-4773(93)90058-6 Stern, 1926, The mutants on the extreme left arm of chromosome two of Drosophila melanogaster, Genetics, 11, 503, 10.1093/genetics/11.6.503 Hamaratoglu, 2006, The tumour-suppressor genes NF2/Merlin and Expanded act through Hippo signalling to regulate cell proliferation and apoptosis, Nat. Cell Biol., 8, 27, 10.1038/ncb1339 Willecke, 2006, The Fat Cadherin acts through the Hippo tumor-suppressor pathway to regulate tissue size, Curr. Biol., 16, 2090, 10.1016/j.cub.2006.09.005 Cho, 2006, Delineation of a Fat tumor suppressor pathway, Nat. Genet., 38, 1142, 10.1038/ng1887 Maitra, 2006, The tumor suppressors Merlin and Expanded function cooperatively to modulate receptor endocytosis and signaling, Curr. Biol., 16, 702, 10.1016/j.cub.2006.02.063 McCartney, 2000, The neurofibromatosis-2 homologue, Merlin, and the tumor suppressor expanded function together in Drosophila to regulate cell proliferation and differentiation, Development, 127, 1315, 10.1242/dev.127.6.1315 McCartney, 1996, Distinct cellular and subcellular patterns of expression imply distinct functions for the Drosophila homologues of moesin and the neurofibromatosis 2 tumor suppressor, merlin, J. Cell Biol., 133, 843, 10.1083/jcb.133.4.843 Muranen, 2005, Cell cycle-dependent nucleocytoplasmic shuttling of the neurofibromatosis 2 tumour suppressor merlin, Oncogene, 24, 1150, 10.1038/sj.onc.1208283 Grönholm, 2006, A functional association between merlin and HEI10, a cell cycle regulator, Oncogene, 25, 4389, 10.1038/sj.onc.1209475 Solberg, 1992, Mapping of the regulatory subunits RI beta and RII beta of cAMP-dependent protein kinase genes on human chromosome 7, Genomics, 14, 63, 10.1016/S0888-7543(05)80284-8 Gronholm, 2003, Merlin links to the cAMP neuronal signaling pathway by anchoring the RIbeta subunit of protein kinase A, J. Biol. Chem., 278, 41167, 10.1074/jbc.M306149200 Hegde, 1993, Regulatory subunits of cAMP-dependent protein kinases are degraded after conjugation to ubiquitin: a molecular mechanism underlying long-term synaptic plasticity, Proc. Natl. Acad. Sci. U. S. A., 90, 7436, 10.1073/pnas.90.16.7436 Goodwin, 1997, Defective learning in mutants of the Drosophila gene for a regulatory subunit of cAMP-dependent protein kinase, J. Neurosci., 17, 8817, 10.1523/JNEUROSCI.17-22-08817.1997 Brandon, 1995, Hippocampal long-term depression and depotentiation are defective in mice carrying a targeted disruption of the gene encoding the RI beta subunit of cAMP-dependent protein kinase, Proc. Natl. Acad. Sci. U. S. A., 92, 8851, 10.1073/pnas.92.19.8851 Hung, 2002, Immunohistochemistry study of human vestibular nerve schwannoma differentiation, Glia, 38, 363, 10.1002/glia.10077 Howe, 2000, Retroviral inhibition of cAMP-dependent protein kinase inhibits myelination but not Schwann cell mitosis stimulated by interaction with neurons, J. Neurosci., 20, 3513, 10.1523/JNEUROSCI.20-10-03513.2000 Ushkaryov, 1992, Neurexins: synaptic cell surface proteins related to the alpha-latrotoxin receptor and laminin, Science, 257, 50, 10.1126/science.1621094 Peles, 1997, Identification of a novel contactin-associated transmembrane receptor with multiple domains implicated in protein–protein interactions, EMBO J., 16, 978, 10.1093/emboj/16.5.978 Einheber, 1997, The axonal membrane protein Caspr, a homologue of neurexin IV, is a component of the septate-like paranodal junctions that assemble during myelination, J. Cell Biol., 139, 1495, 10.1083/jcb.139.6.1495 Bellen, 1998, Neurexin IV, caspr and paranodin-novel members of the neurexin family: encounters of axons and glia, Trends Neurosci., 21, 444, 10.1016/S0166-2236(98)01267-3 Gollan, 2003, Caspr regulates the processing of contactin and inhibits its binding to neurofascin, J. Cell Biol., 163, 1213, 10.1083/jcb.200309147 Menegoz, 1997, Paranodin, a glycoprotein of neuronal paranodal membranes, Neuron, 19, 319, 10.1016/S0896-6273(00)80942-3 Denisenko-Nehrbass, 2003, Association of Caspr/paranodin with tumour suppressor schwannomin/merlin and beta1 integrin in the central nervous system, J. Neurochem., 84, 209, 10.1046/j.1471-4159.2003.01503.x Goutebroze, 2000, Cloning and characterization of SCHIP-1, a novel protein interacting specifically with spliced isoforms and naturally occurring mutant NF2 proteins, Mol. Cell. Biol., 20, 1699, 10.1128/MCB.20.5.1699-1712.2000 Kuroda, 1999, Mammalian homologue of the Caenorhabditis elegans UNC-76 protein involved in axonal outgrowth is a protein kinase C zeta-interacting protein, J. Cell Biol., 144, 403, 10.1083/jcb.144.3.403 Kwasnicka-Crawford, 2006, IQCJ-SCHIP1, a novel fusion transcript encoding a calmodulin-binding IQ motif protein, Biochem. Biophys. Res. Commun., 350, 890, 10.1016/j.bbrc.2006.09.136 Den Bakker, 2001, Truncated NF2 proteins are not detected in meningiomas and schwannomas, Neuropathology, 21, 168, 10.1046/j.1440-1789.2001.00394.x Aznar, 2004, Rho GTPases: potential candidates for anticancer therapy, Cancer Lett., 206, 181, 10.1016/j.canlet.2003.08.035 Shirai, 2007, Small GTP-binding proteins and mitogen-activated protein kinases as promising therapeutic targets of vascular remodeling, Curr. Opin. Nephrol. Hypertens., 16, 111, 10.1097/MNH.0b013e3280148e4f Fritz, 2006, Rho GTPases: promising cellular targets for novel anticancer drugs, Curr. Cancer Drug Targets, 6, 1, 10.2174/156800906775471752 Maruta, 1999, Cytoskeletal tumor suppressors that block oncogenic RAS signaling, Ann. N. Y. Acad. Sci., 886, 48, 10.1111/j.1749-6632.1999.tb09399.x He, 2001, Signal therapy for RAS-induced cancers in combination of AG 879 and PP1, specific inhibitors for ErbB2 and Src family kinases, that block PAK activation, Cancer J., 7, 191 Hirokawa, 2005, Signal therapy of NF1-deficient tumor xenograft in mice by the anti-PAK1 drug FK228, Cancer Biol. Ther., 4, 379, 10.4161/cbt.4.4.1649 Hirokawa, 2007, Signal therapy of human pancreatic cancer and NF1-deficient breast cancer xenograft in mice by a combination of PP1 and GL-2003, anti-PAK1 drugs (Tyr-kinase inhibitors), Cancer Lett., 245, 242, 10.1016/j.canlet.2006.01.018 Shahbazian, 2006, The mTOR/PI3K and MAPK pathways converge on eIF4B to control its phosphorylation and activity, EMBO J., 25, 2781, 10.1038/sj.emboj.7601166 Nguyen, 2001, Hierarchy of merlin and ezrin N- and C-terminal domain interactions in homo- and heterotypic associations and their relationship to binding of scaffolding proteins EBP50 and E3KARP, J. Biol. Chem., 276, 7621, 10.1074/jbc.M006708200